Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition Across Diverse Patient Populations in Gynecology Practices at Penn Medicine

NCT05721326 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT05721326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05721326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition Across Diverse Patient Populations in Gynecology Practices at Penn Medicine
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Not applicable
Overall status
Completed
Start date
May 1, 2023
Completion date
December 31, 2025
Enrollment
1,283 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, gene mutation-related cancer, genetic predisposition to disease, hereditary breast and ovarian cancer, hereditary cancer syndrome, hereditary diseases, ovarian cancer